CELU חוב כולל להון Celularity

Celularity Inc. (CELU) is implementing a unique method of extracting placental stem cells to combat oncology and Crohn's disease without the need for donors. This chart of the price trend based on the total debt-to-equity ratio, which stands at 0.00, confirms the company's financial dynamics. Management aims to monetize aesthetic and medical developments, while the product portfolio focuses on scalable regenerative therapy.

This ratio serves as a critical filter when stress-testing the issuer's debt sustainability as part of fundamental screening. It measures the proportion of total liabilities to net equity, whereby the level of leverage demonstrates the extent to which the development of the placenta-cell-based cancer therapy innovation platform is funded by external loans rather than the internal assets of Celularity Inc. (CELU).